Sutro Biopharma (NASDAQ:STRO) and Cardio Diagnostics (NASDAQ:CDIO) Head-To-Head Analysis

Sutro Biopharma (NASDAQ:STRO) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares Sutro Biopharma and Cardio Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48 million	3.42	-$191.09 million	($11.97)	-1.77
Cardio Diagnostics	$10,000.00	552.04	-$6.50 million	($2.92)	-0.64

Cardio Diagnostics has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sutro Biopharma and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Risk and Volatility

Sutro Biopharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Sutro Biopharma and Cardio Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1	0	10	2	3.00
Cardio Diagnostics	1	0	0	0	1.00

Sutro Biopharma currently has a consensus price target of $47.30, indicating a potential upside of 123.80%. Given Sutro Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Cardio Diagnostics.

Insider & Institutional Ownership

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sutro Biopharma beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.

About Sutro Biopharma

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.